Strides Pharma Science Limited has moved back its timeline for achieving $225-250m in revenues from the US by a year to FY23, following significant price erosion amid intensified competition in the US during the second quarter of fiscal 2022, which began on 1 April.
In response, Strides is shifting its focus away from niche products in the US and will leverage the portfolio acquired...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?